We claim:

1. An isolated monoclonal antibody that binds to an epitope of human tissue factor pathway inhibitor (SEQ ID NO:1), wherein said epitope comprises one or more residues selected from the group consisting of Glu100, Glu101, Asp102, Pro103, Gly104, Ile105, Cys106, Arg107, Gly108, Tyr109, Lys126, Gly128, Gly129, Cys130, Leu131, Gly132, and Asn133 of SEQ ID NO:1.
2. The isolated monoclonal antibody of claim 1, wherein said epitope comprises residue Ile105 of SEQ ID NO:1.
3. The isolated monoclonal antibody of claim 1, wherein said epitope comprises residue Ile105 and Asp102 of SEQ ID NO:1.
4. The isolated monoclonal antibody of claim 1, wherein said epitope comprises residue Ile105, Asp102 and Leu131 of SEQ ID NO:1.
5. The isolated monoclonal antibody of claims 2-4, wherein the epitope further comprises one or more residues selected from the group consisting of Glu100, Glu101, Asp102, Pro103, Gly104, Cys106, Arg107, Gly108, Tyr109, Lys126, Gly128, Gly129, Cys130, Leu131, Gly132, and Asn133 of SEQ ID NO:1.
6. An isolated monoclonal antibody that binds to an epitope of human tissue factor pathway inhibitor (SEQ ID NO:1), wherein said epitope comprises two amino acid loops linked by a disulfide bridge between residues Cys106 and Cys130 of SEQ ID NO:1.
7. The isolated monoclonal antibody of claim 6, wherein said epitope further comprises one or more residues selected from the group consisting of Glu100, Glu101, Asp102, Pro103, Gly104, Ile105, Cys106, Arg107, Gly108, Tyr109, Lys126, Gly128, Gly129, Cys130, Leu131, Gly132, and Asn133 of SEQ ID NO:1.
8. The isolated monoclonal antibody of claim 7, wherein said epitope comprises residue Ile105 of SEQ ID NO:1.
9. The isolated monoclonal antibody of claims 7, wherein the epitope comprises residue Asp102 of SEQ ID NO:1.
10. The isolated monoclonal antibody of claim 7, wherein the epitope comprises residue Leu131 of SEQ ID NO:1.
11. The isolated monoclonal antibody of claim 8-10, wherein the epitope further comprises one or more residues selected from the group consisting of Glu100, Glu101, Asp102,

Pro103, Gly104, Ile105, Cys106, Arg107, Gly108, Tyr109, Lys126, Gly128, Gly129, Cys130, Leu131, Gly132, and Asn133 of SEQ ID NO:1.

12. An isolated monoclonal antibody that binds to an epitope of human tissue factor pathway inhibitor (SEQ ID NO:1), wherein said epitope comprises one or more residues of Kunitz domain 1 and one or more residues of Kunitz domain 2.

13. The isolated monoclonal antibody of claim 12, wherein the residue of Kunitz domain 1 comprises one or more residues selected from the group consisting of Asp31, Asp32, Gly33, Pro34, Cys35, Lys36, Cys59, Glu60 and Asn62.

14. The isolated monoclonal antibody of claim 13, wherein the residue of Kunitz domain 1 comprises residue Pro34.

15. The isolated monoclonal antibody of claim 13, wherein the residues of Kunitz domain 1 comprise residues Pro34 and Glu60.

16. The isolated monoclonal antibody of claim 13, wherein the residues of Kunitz domain 1 comprise residues Pro34, Lys36 and Glu60.

17. The isolated monoclonal antibody of any of claims 14-16, wherein the residues of Kunitz domain 1 comprise one or more residues selected from the group consisting of Asp31, Asp32, Gly33, Cys35, Lys36, Cys59, Glu60 and Asn62.

18. The isolated monoclonal antibody of claim 12, wherein the residue of Kunitz domain 2 comprises one or more residues selected from the group consisting of Glu100, Glu101, Pro103, Gly104, Ile105, Cys106, Arg107, Gly108, Tyr109, Phe114, Asn116, Glu123, Arg124, Lys126, Tyr127 and Gly128.

19. The isolated monoclonal antibody of claim 18, wherein the residue of Kunitz domain 2 comprises residue Arg107.

20. The isolated monoclonal antibody of claim 18, wherein the residue of Kunitz domain 2 comprises residue Glu101.

21. The isolated monoclonal antibody of claim 18, wherein the residue of Kunitz domain 2 comprises residue Tyr109.

22. The isolated monoclonal antibody of any of clams 19-21, wherein the residues of Kunitz domain 2 further comprise one or more residues selected from the group consisting of Glu100, Glu101, Pro103, Gly104, Ile105, Cys106, Arg107, Gly108, Tyr109, Phe114, Asn116, Glu123, Arg124, Lys126, Tyr127 and Gly128

23. The isolated monoclonal antibody of claim 12, wherein the residue of Kunitz domain 1 comprises one or more residues selected from the group consisting of Asp31, Asp32, Gly33, Pro34, Cys35, Lys36, Cys59, Glu60 and Asn62 and wherein the residue of Kunitz domain 2 comprises one or more residues selected from the group consisting of Glu100, Glu101, Pro103, Gly104, Ile105, Cys106, Arg107, Gly108, Tyr109, Phe114, Asn116, Glu123, Arg124, Lys126, Tyr127 and Gly128.

24. An isolated monoclonal antibody that binds to an epitope of human tissue factor pathway inhibitor (SEQ ID NO:1), wherein said epitope comprises two amino acid loops linked by a disulfide bridge between residues Cys35 and Cys59 of SEQ ID NO:1.

25. The isolated monoclonal antibody of claim 24, wherein said epitope further comprises one or more residues of Kunitz domain 1 and one or more residues of Kunitz domain 2.

26. The isolated monoclonal antibody of claim 25, wherein the residue of Kunitz domain 1 comprises one or more residues selected from the group consisting of Asp31, Asp32, Gly33, Pro34, Cys35, Lys36, Cys59, Glu60 and Asn62.

27. The isolated monoclonal antibody of claim 25, wherein the residue of Kunitz domain 2 comprises one or more residues selected from the group consisting of Glu100, Glu101, Pro103, Gly104, Ile105, Cys106, Arg107, Gly108, Tyr109, Phe114, Asn116, Glu123, Arg124, Lys126, Tyr127 and Gly128.

28. The isolated monoclonal antibody of claim 22, wherein the residue of Kunitz domain 1 comprises one or more residues selected from the group consisting of Asp31, Asp32, Gly33, Pro34, Cys35, Lys36, Cys59, Glu60 and Asn62 and wherein the residue of Kunitz domain 2 comprises one or more residues selected from the group consisting of Glu100, Glu101, Pro103, Gly104, Ile105, Cys106, Arg107, Gly108, Tyr109, Phe114, Asn116, Glu123, Arg124, Lys126, Tyr127 and Gly128.

29. An isolated monoclonal antibody that binds to TFPI, wherein the isolated monoclonal antibody is competitive with any of the isolated monoclonal antibodies of claims 1 to 28 for binding to TFPI.

30. An isolated bispecific antibody that binds to TFPI, wherein the bispecific antibody is competitive with any of the isolated monoclonal antibodies of claims 1 to 28 for binding to TFPI.

31. A pharmaceutical composition comprising a therapeutically effective amount of the monoclonal antibody of any of claims 1-30 and a pharmaceutically acceptable carrier.

32. A pharmaceutical composition comprising a therapeutically effective amount of at least two monoclonal antibodies of any of claims 1-30 and a pharmaceutically acceptable carrier.

33. The pharmaceutical composition of claim 32, wherein a first monoclonal antibody comprises the isolated monoclonal antibody of claim 1, and a second monoclonal antibody comprises the isolated monoclonal antibody of claim 12.

34. A method for treating genetic or acquired deficiencies or defects in coagulation comprising administering a therapeutically effective amount of the pharmaceutical composition of any of claims 30-32 to a patient.

35. The method of claim 34 wherein the method treats hemophilia A, B or C.

36. A method for shortening bleeding time comprising administering a therapeutically effective amount of the pharmaceutical composition of any of claims 31-33 to a patient.

37. An isolated nucleic acid molecule encoding an antibody that binds to an epitope of human tissue factor pathway inhibitor (SEQ ID NO: 1) encoding said isolated monoclonal antibody of any of claims 1-29.

CLAIMS

1. An invention not claimed in any divisional application.